Myoma Uteri

myomauteri-1-0-25kapak

Myoma Uteri and Genetic Factors: A Clinical Genetic Perspective, Genetic and Molecular Mechanisms

Serdar Ceylaner1
Gülay Ceylaner2

1Lokman Hekim University, Faculty of Medicine, Department of Medical Genetics, Ankara, Türkiye
2Intergen Genetics and Rare Diseases Diagnosis Research and Application Center, Medical Genetics Clinic, Ankara, Türkiye

Ceylaner S, Ceylaner G. Myoma Uteri and Genetic Factors: a Clinical Genetic Perspective, Genetic and Molecular Mechanisms. Yavuz AF, ed. Myoma Uteri. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.21-26.

ABSTRACT

Uterine myomas are among the most common benign tumors in women of reproductive age. The development of these tumors involves a complex interplay of hormonal, genetic, and environmental factors. Genetic studies have revealed that somatic mutations, epigenetic regulations, inflammatory cytokines, and associations with hereditary syndromes play significant roles in the pathogenesis of myomas. Understanding the genetic and molecular mechanisms of uterine myomas is crucial for both diagnosis and targeted treatment strategies. This study explores various mechanisms, including hor- mone receptor signaling pathways, DNA repair mechanisms, growth factors, epigenetic regulations, and immune responses.

Keywords: Leiomyomas; Genetics; Epigenetics

Referanslar

  1. Altinkaya SO, Avcioglu SN, Sezer SD, Ceylaner S. Analysis of TP53 gene in uterine myomas: No mutations but P72R polymorphism is associated with myoma development. J Obstet Gynaecol Res. 2019 Oct;45(10):2088-2094. [Crossref]  [PubMed]
  2. Upadhyay S, Dubey PK. Gene variants polymorphisms and uterine leiomyoma: an updated review. Front Genet. 2024 Mar 20;15:1330807. [Crossref]  [PubMed]  [PMC]
  3. Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022 May;29(5):946-960. [Crossref]  [PubMed]  [PMC]
  4. Aimagambetova G, Bapayeva G, Ukybassova T, Zemlyanskiy V, Gusmanov A, Terzic M. The role of VEGF and TGF-β blood levels for fibroid shrinkage, menorrhagia score, and quality of life improvement after uterine artery embolization for uterine fibroids: a study protocol. Front Med (Lausanne). 2024 Aug 6;11:1382822. [Crossref]  [PubMed]  [PMC]
  5. Zannotti A, Greco S, Pellegrino P, Giantomassi F, Delli Carpini G, Goteri G, Ciavattini A, Ciarmela P. Macrophages and Immune Responses in Uterine Fibroids. Cells. 2021 Apr 22;10(5):982. [Crossref]  [PubMed]  [PMC]
  6. Afrin S, El Sabah M, Manzoor A, Miyashita-Ishiwata M, Reschke L, Borahay MA. Adipocyte coculture induces a pro-inflammatory, fibrotic, angiogenic, and proliferative microenvironment in uterine leiomyoma cells. Biochim Biophys Acta Mol Basis Dis. 2023 Jan 1;1869(1):166564. [Crossref]  [PubMed]  [PMC]
  7. Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, Al-Hendy A. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 Jul 13;43(4):678-719. [Crossref]  [PubMed]  [PMC]
  8. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res. 2003 Mar 15;63(6):1351-8. [PubMed]
  9. Borahay MA, Al-Hendy A, Kilic GS, Boehning D. Signaling Pathways in Leiomyoma: Understanding Pathobiology and Implications for Therapy. Mol Med. 2015 Apr 13;21(1):242-56. [Crossref]  [PubMed]  [PMC]
  10. Makker A, Goel MM, Mahdi AA, Bhatia V, Das V, Agarwal A, Pandey A. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes PTEN & LKB1 in human uterine leiomyomas. Indian J Med Res. 2016 May;143(- Supplement):S112-S119. [Crossref]  [PubMed]  [PMC]